Contact details:

Coordinator:

Chantal Mathieu

KU Leuven, Laboratory of Clinical and Experimental Endocrinology

Herestraat 49, O&N1, box 902

B-3000 Leuven

Tel +32-16-34.60.23

e-mail chantal.mathieu@med.kuleuven.be

Administrative coordinator:

Lut Overbergh

KU Leuven, Laboratory of Clinical and Experimental Endocrinology

Herestraat 49, O&N1, box 902

B-3000 Leuven

Tel +32-16-34.61.63

e-mail lut.overbergh@med.kuleuven.be

Website:

www.naimit.eu

List of Beneficiaries:

Beneficiary no.	Beneficiary name	Beneficiary short name	Scientific team leader	Town	Country
1 coordinator	Katholieke Universiteit Leuven	KULeuven	Mathieu, Chantal	Leuven	Belgium
2	Johann Wolfgang von Goethe Universität	GUF	Badenhoop, Klaus	Frankfurt am Main	Germany
3A	University of Bristol	UNIVBRIS	Bingley, Penelope J.	Bristol	United Kingdom
3B	University of Bristol	UNIVBRIS	Dayan, Colin M.[a]	Bristol	United Kingdom
4	Fundacao Calouste Gulbenkian	FCG-IGC	Demengeot, Jocelyne	Lisboa	Portugal
5	Universita degli Studi di Siena	UNISI	Dotta, Francesco	Siena	Italy
6	Universite Libre de Bruxelles	ULB	Eizirik, Decio L.	Bruxelles	Belgium
7	Medizinische Hochschule Hannover	MHH	Lenzen, Sigurd	Hannover	Germany
8	Universita di Pisa	UPI	Marchetti, Piero	Pisa	Italy
9	King's College London	KCL	Peakman, Mark	London	United Kingdom
10A	Academisch Ziekenhuis Leiden – Leids Universitair Medisch Centrum	LUMC	Roep, Bart O.	Leiden	The Netherlands
10B	Academisch Ziekenhuis Leiden – Leids Universitair Medisch Centrum	LUMC	Oostendorp, J[c]	Leiden	The Netherlands
11	Cambridge Institute for Medical Research	CIMR	Todd, John	Cambridge	United Kingdom
12	ActoGeniX NV	AGX	Rottiers, Pieter	Zwijnaarde (Ghent)	Belgium
~~13~~[d]	~~DanDrit Biotech~~	~~DanDrit~~	~~Zocca, Mai-Britt~~	~~Copen-hagen~~	~~Denmark~~
14	Immunocore	IMC	Jakobsen, Bent	Abingdon (Oxford)	United Kingdom
15	Cardiff University	CU	Dayan, Colin M.[b]	Cardiff	United Kingdom

a. From month 1 till month 9
b. From month 10 onwards
c. from month 21 onwards
d. from month 1 till month 20



Figure 1. A proposed model for the pathogenesis of T1DM. Viral infections or other triggers can initiate a hyperactive response towards the beta-cells, releasing beta-cell antigens and possibly also chemokines which may contribute to the homing and activation of T lymphocytes and APC into the islets. The beta-cell antigens are presented in association with class II MHC molecules to CD4+ T lymphocytes after being processed by DCs. DCs release IL-12, activating CD4+ T effector (Te) cells, which in turn release IFN-γ and IL-2. Migratory macrophages and CD8+ T lymphocytes become cytotoxic (Tc) in response to these cytokines and release IL-1ß, TNF-α, IFN-γ, free radicals and chemokines. CD8+ Tc cells recognise beta-cell antigens in association with class I MHC molecules. Beta-cells can also be destroyed by Fas-mediated cell death and/or granzyme and perforin. Tregs are dysfunctional or not sufficiently present.



Figure 2. Number of visitors of the NAIMIT website (www.naimit.eu).



Figure 3. Number of publications in the frame of NAIMIT, in relation to the number of collaborating partners.

Figure 4. Open door day 2013 at the European Commission